检索范围:
排序: 展示方式:
null
《医学前沿(英文)》 2013年 第7卷 第3期 页码 306-315 doi: 10.1007/s11684-013-0279-x
Allogeneic hematopoietic stem cell transplantation (HSCT) is one of the most effective options for hematological malignancies, and human leukocyte antigen-partially matched related donors (PMRDs) are a valuable option for HSCT. Several protocols (with or without ex vivo T-cell depletion (TCD)) have been established worldwide. TCD including CD34+positive selection and CD3/CD19 depletion has successfully overcome the human leukocyte antigen disparity. However, TCD is associated with prolonged immune deficiencies, increased risks of infectious complications, and high transplantation-related mortality. PMRD HSCT without ex vivo TCD is well developed, and numerous patients have benefitted from it. Here, we review the literature on PMRD HSCT.
关键词: partially matched related donor hematopoietic stem cell transplantation allogeneic
In vivo imaging of hematopoietic stem cell development in the zebrafish
Panpan Zhang, Feng Liu
《医学前沿(英文)》 2011年 第5卷 第3期 页码 239-247 doi: 10.1007/s11684-011-0123-0
关键词:
hematopoietic stem cell
hematopoiesis
null
《医学前沿(英文)》 2018年 第12卷 第2期 页码 224-228 doi: 10.1007/s11684-017-0538-3
Bronchiolitis obliterans syndrome (BOS) after hematopoietic stem cell transplantation (HSCT) is a major cause of morbidity and mortality with limited treatment options. Lung transplantation (LTX) has been rarely reported as a treatment option for selected HSCT recipients with this problem. In the present study, we reported six patients who underwent LTX due to BOS after HSCT (two females, four males) from January 2012 to December 2014 in our center. The median time from HSCT to diagnosis of BOS was 2.5 years (ranging from 1 to 5 years). At a median time of 4 years (ranging from 2 to 5 years) after diagnosis of BOS, four patients received bilateral sequential LTX, and two patients received single LTX. One of the recipients suffered from mild acute rejection after LTX, another suffered from primary lung graft dysfunction on post-operation day 2, and three experienced fungal infections. The median time for follow-up after LTX was 19.5 months (ranging from 12 to 39 months). At present, all patients are alive with good functional capacity and no relapse of BOS and hematologic malignancy conditions. Patients who received bilateral LTX have better pulmonary functions than patients who received single LTX.
关键词: bronchiolitis obliterans syndrome (BOS) hematopoietic stem cell transplantation (HSCT) lung transplantation (LTX)
《医学前沿(英文)》 2022年 第16卷 第6期 页码 957-968 doi: 10.1007/s11684-021-0910-1
关键词: skin and soft tissue infections hematopoietic stem cell transplantation risk stratification system mortality
Meng Lv, Yingjun Chang, Xiaojun Huang
《医学前沿(英文)》 2019年 第13卷 第1期 页码 45-56 doi: 10.1007/s11684-017-0595-7
关键词: haploidentical hematopoietic stem cell transplantation conditioning graft-versus-host disease relapse infection donor selection
null
《医学前沿(英文)》 2015年 第9卷 第3期 页码 304-311 doi: 10.1007/s11684-015-0400-4
In the tyrosine kinase inhibitor (TKI) era, imatinib is the first-line therapy for patients with chronic myeloid leukemia (CML) in chronic or accelerated phase. Although second-generation TKIs (TKI2), including dasatinib and nilotinib, are appropriate treatment regimens for patients with disease that progressed to accelerated phase following imatinib therapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative therapy. This study retrospectively analyzed the efficacy of TKI2 and HSCT for treatment of CML in accelerated phase. Ninety-three patients with CML registered in the Chinese CML alliance database from February 2001 to February 2014 were enrolled and divided into the TKI2 (n?=?33) and allo-HSCT (n?=?60) groups. In the TKI2 group, 26 and 7 patients received nilotinib and dasatinib, respectively, as initial TKI2 and 11 patients transferred to the alternative TKI2 after failure to one TKI2. In the allo-HSCT group, 22 (36.7%), 35 (58.3%), and 3 (10%) patients underwent allo-HSCT from an HLA-matched sibling donor, HLA mismatched/haploidentical donor, and unrelated donor, respectively. All patients in the HSCT group were engrafted. Overall, 69.7%, 48.5%, and 45.5% of patients presented hematological, cytogenetic, and major molecular responses, respectively, to at least one of TKI2. All 60 patients (100%) achieved CHR and cytogenetic response in the HSCT group. Patients in the TKI2 group exhibited lower 5-year overall survival rate (42.9% vs. 86.4%, P = 0.002), 5-year event-free survival rate (14.3% vs. 76.1%, P<0.001), and 5-year progression-free survival (28.6% vs. 78.1%, P<0.001) than those in the allo-HSCT group. Multivariate analysis showed that male sex and TKI2therapy were predictors of poor overall survival, whereas hemoglobin<100 g/L and TKI2 therapy were predictors of poor event-free survival and progression-free survival. These results indicated that allo-HSCT may be superior to nilotinib and dasatinib for adult patients with CML in accelerated phase.
关键词: chronic myeloid leukemia imatinib dasatinib nilotinib allogeneic hematopoietic stem cell transplantation
null
《医学前沿(英文)》 2015年 第9卷 第4期 页码 412-420 doi: 10.1007/s11684-015-0423-x
Genetic mutations are considered to drive the development of acute myeloid leukemia (AML). With the rapid progress in sequencing technologies, many newly reported genes that are recurrently mutated in AML have been found to govern the initiation and relapse of AML. These findings suggest the need to distinguish the driver mutations, especially the most primitive single mutation, from the subsequent passenger mutations. Recent research on DNA methyltransferase 3A (DNMT3A) mutations provides the first proof-of-principle investigation on the identification of preleukemic stem cells (pre-LSCs) in AML patients. Although DNMT3A mutations alone may only transform hematopoietic stem cells into pre-LSCs without causing the full-blown leukemia, the function of this driver mutation appear to persist from AML initiation up to relapse. Therefore, identifying and targeting preleukemic mutations, such as DNMT3A mutations, in AML is a promising strategy for treatment and reduction of relapse risk.
关键词: preleukemic stem cell acute myeloid leukemia relapse DNMT3A
Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity
Chuanfeng Wu, Cynthia E. Dunbar
《医学前沿(英文)》 2011年 第5卷 第4期 页码 356-371 doi: 10.1007/s11684-011-0159-1
关键词: gene therapy hematopoietic stem cells insertional mutagenesis genotoxicity induced pluripotent stem cell
Autologous peripheral hematopoietic stem-cell transplantation in a patient with refractory pemphigus
SUN Ledong, SUN Jing, ZENG Kang, MENG Fanyi, DIAO Youtao, XU Dan, HUANG Liang, ZHAO Jie, Liu Qifa
《医学前沿(英文)》 2008年 第2卷 第2期 页码 191-194 doi: 10.1007/s11684-008-0036-8
关键词: serological activity leukapheresis peripheral hematopoietic cyclophosphamide resistance
Positive stool culture could predict the clinical outcomes of haploidentical hematopoietic stem cell
Lijuan Hu, Qi Wang, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Kaiyan Liu, Hui Wang, Xiaojun Huang, Xiaodong Mo
《医学前沿(英文)》 2019年 第13卷 第4期 页码 492-503 doi: 10.1007/s11684-019-0681-0
关键词: haploidentical hematopoietic stem cell transplantation stool culture Candida
Xiaodong Mo, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang
《医学前沿(英文)》 2019年 第13卷 第3期 页码 354-364 doi: 10.1007/s11684-018-0665-5
关键词: donor leukocyte infusion hematopoietic stem cell transplantation interferon-
Xiaodong Mo, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang
《医学前沿(英文)》 2019年 第13卷 第2期 页码 238-249 doi: 10.1007/s11684-017-0599-3
关键词: interferon-α hematopoietic stem cell transplantation minimal residual disease donor lymphocyte infusion
Ling Wang, Lining Wang, Xing Fan, Wei Tang, Jiong Hu
《医学前沿(英文)》 2021年 第15卷 第1期 页码 108-115 doi: 10.1007/s11684-019-0730-8
关键词: post-transplantation cyclophosphamide allogeneic hematopoietic stem cell transplantation lymphoid malignancies
The unregulated commercialization of stem cell treatments: a global perspective
Douglas Sipp
《医学前沿(英文)》 2011年 第5卷 第4期 页码 348-355 doi: 10.1007/s11684-011-0150-x
关键词: stem cell tourism medical ethics stem cell policy and regulation alternative medicine
The regulatory sciences for stem cell-based medicinal products
null
《医学前沿(英文)》 2014年 第8卷 第2期 页码 190-200 doi: 10.1007/s11684-014-0323-5
Over the past few years, several new achievements have been made from stem cell studies, many of which have moved up from preclinical stages to early, or from early to middle or late, stages thanks to relatively safe profile and preliminary evidence of effectiveness. Moreover, some stem cell-based products have been approved for marketing by different national regulatory authorities. However, many critical issues associated mainly with incomplete understanding of stem cell biology and the relevant risk factors, and lack of effective regulations still exist and need to be urgently addressed, especially in countries where establishment of appropriate regulatory system just commenced. More relevantly, the stem cell regulatory sciences need to be established or improved to more effectively evaluate quality, safety and efficacy of stem cell products, and for building up the appropriate regulatory framework. In this review, we summarize some new achievements in stem cell studies, especially the preclinical and clinical studies, the existing regulations, and the associated challenges, and we then propose some considerations for improving stem cell regulatory sciences with a goal of promoting the steadfast growth of the well-regulated stem cell therapies abreast of evolvement of stem cell sciences and technologies.
关键词: stem cell-based medicinal products (SCMPs) stem cell therapy (SCT) safety effectiveness standards guidelines regulatory science
标题 作者 时间 类型 操作
Advancement of human leukocyte antigen-partially matched related hematopoietic stem cell transplantation
null
期刊论文
Lung transplantation for bronchiolitis obliterans syndrome after allogenic hematopoietic stem cell transplantation
null
期刊论文
Risk stratification system for skin and soft tissue infections after allogeneic hematopoietic stem cell
期刊论文
Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoieticstem cell transplantation
Meng Lv, Yingjun Chang, Xiaojun Huang
期刊论文
Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult
null
期刊论文
Mutant DNA methylation regulators endow hematopoietic stem cells with the preleukemic stem cell property
null
期刊论文
Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity
Chuanfeng Wu, Cynthia E. Dunbar
期刊论文
Autologous peripheral hematopoietic stem-cell transplantation in a patient with refractory pemphigus
SUN Ledong, SUN Jing, ZENG Kang, MENG Fanyi, DIAO Youtao, XU Dan, HUANG Liang, ZHAO Jie, Liu Qifa
期刊论文
Positive stool culture could predict the clinical outcomes of haploidentical hematopoietic stem cell
Lijuan Hu, Qi Wang, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Kaiyan Liu, Hui Wang, Xiaojun Huang, Xiaodong Mo
期刊论文
Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoieticstem cell transplantation
Xiaodong Mo, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang
期刊论文
unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoieticstem cell transplantation
Xiaodong Mo, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang
期刊论文
intravenous busulfan conditioning with post-transplantation cyclophosphamide for allogeneic peripheral stemcell transplantation for adult patients with lymphoid malignancies: a prospective single-arm phase II
Ling Wang, Lining Wang, Xing Fan, Wei Tang, Jiong Hu
期刊论文